biostudies-literatureZhang YCapital Health Research and Development of Special Fund1749-1766https://www.ebi.ac.uk/biostudies/studies/S-EPMC9588101biostudies-literatureUnknown11(4)<h4>Introduction</h4>Clopidogrel resistance causes recurrent stroke. However, outcomes of modified antiplatelet medications to prevent recurrent ischemic stroke are not well known.<h4>Methods</h4>Patients who received clopidogrel with and without modification as initial treatment for stroke were recruited and compared. The primary outcome was ischemic stroke and myocardial infarction at the 1-year follow-up. The secondary outcome was bleeding complications.<h4>Results</h4>Overall, 206 patients treated with clopidogrel were enrolled and were divided into the modification (n = 39) and no modification (n = 167) groups. There was a significant difference in the incidence of severe cerebral arterial stenosis between the two groups (modification group, 16/39, 41.03%; no modification group, 36/16Neurology and therapyVerifynow P2Y₁₂ PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study.PMC95881012014-1-4092Qiao SZhang YHu HFan DfalseVerifynow P2Y₁₂ PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study.<h4>Introduction</h4>Clopidogrel resistance causes recurrent stroke. However, outcomes of modified antiplatelet medications to prevent recurrent ischemic stroke are not well known.<h4>Methods</h4>Patients who received clopidogrel with and without modification as initial treatment for stroke were recruited and compared. The primary outcome was ischemic stroke and myocardial infarction at the 1-year follow-up. The secondary outcome was bleeding complications.<h4>Results</h4>Overall, 206 patients treated with clopidogrel were enrolled and were divided into the modification (n = 39) and no modification (n = 167) groups. There was a significant difference in the incidence of severe cerebral arterial stenosis between the two groups (modification group, 16/39, 41.03%; no modification group, 36/162022-01-01T00:00:00Z2022 Dec2025-04-19T15:40:37.228Z2025-04-19T15:40:37.228ZS-EPMC95881013616341510.1007/s40120-022-00406-z